(6-bromohexyl)triphenylphosphonium bromide | 83152-22-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (6-bromohexyl)triphenylphosphonium bromide
• 英文别名: Phosphonium, (6-bromohexyl)triphenyl-, bromide；6-bromohexyl(triphenyl)phosphanium;bromide
• CAS: 83152-22-1
• 化学式: Br*C₂₄H₂₇BrP
• 分子量: 506.26
• InChiKey: RJXLPJGHUJHULP-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  2.94
• 重原子数：
  27
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• WGK Germany：
  3
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温下密封保存，并确保环境干燥。

反应信息

• 作为反应物：
  描述：

  (6-bromohexyl)triphenylphosphonium bromide 在 氢溴酸 作用下， 生成 (6-hydroxyhexyl)triphenylphosphonium bromide
  参考文献：
  名称：

  ω-Thioacetylalkylphosphonium salts: Precursors for the preparation of phosphonium-functionalised gold nanoparticles

  摘要：

  Two new omega-thioacetylalkylphosphonium salts that function as masked cationic alkanethiolate ligands for the stabilisation of gold nanoparticles have been prepared. Both (3-thioacetylpropyl) triphenylphosphonium bromide and (6-thioacetylhexyl) triphenylphosphonium bromide were shown to form water-soluble gold nanoparticles of ca. 5-10 nm in size that are stable for up to six months. The related (3-thioacetylpropyl) diphenylphosphine oxide was also prepared but did not act as a stabilising ligand in gold nanoparticle formation. (C) 2008 Elsevier B. V. All rights reserved.

  DOI：

  10.1016/j.jorganchem.2008.08.009
• 作为产物：
  描述：

  (6-hydroxyhexyl)triphenylphosphonium bromide 在 氢溴酸 作用下， 以 水 、 甲苯 为溶剂， 反应 12.0h， 以88%的产率得到(6-bromohexyl)triphenylphosphonium bromide
  参考文献：
  名称：

  31 P NMR光谱法测定线粒体pH的新型氨基膦酸酯的合成与生物学表征。

  摘要：

  设计并合成了一系列将二乙氧基磷酰基与烷基连接的三苯基溴化tail尾部结合的线粒体靶向α-氨基膦酸酯，并对其pH敏感的31 P NMR特性和体内外生物学活性进行了评估。结果表明，许多这些线粒体氨基膦酸酯的p K a值符合线粒体pH范围，短暂弛豫和与敏感的31相容的化学位移参数P NMR检测以及对绿藻和鼠成纤维细胞培养物的低细胞毒性。在这些化合物中，有两种选择的化合物在向分离的大鼠肝脏灌注后，在胞质和线粒体位点以NMR可检测的水平分布，对细胞能量和有氧呼吸没有有害影响。该研究为线粒体/细胞质pH梯度原位光谱实时监测的进一步发展提供了新的分子支架。

  DOI：

  10.1021/jm301866e

文献信息

• Phosphonioalkylthiosulfate zwitterions—new masked thiol ligands for the formation of cationic functionalised gold nanoparticles
  作者：Yon Ju-Nam、Neil Bricklebank、David W. Allen、Philip H. E. Gardiner、Mark E. Light、Michael B. Hursthouse

  DOI：10.1039/b610480k

  日期：——

  We report the synthesis and structural characterisation of a new family of stable phosphonioalkylthiosulfate zwitterions, R3P+(CH2)nS2O3− (R = Ph or Bu, n = 3,4,6, 8 or 10) which behave as cationic masked thiolate ligands with applications in the functionalisation of gold nanoparticles, having potential as new diagnostic biorecognition systems. The ligands were prepared by treatment of ω-bromoalkylphosphonium salts with sodium thiosulfate. The crystal and molecular structures of the zwitterions (R = Ph, n = 3) and (R = Bu, n = 3) were determined. A series of phosphonioalkanethiolate-capped gold nanoparticles dispersed in water was prepared by borohydride reduction of potassium tetrachloroaurate in the presence of the zwitterions in a dichloromethane–water system. UV-visible spectroscopy and scanning transmission electron-microscopy indicated that capped nanoparticles of ca. 5 nm diameter were present.

  我们报道了一类新型稳定的膦氧烷基硫代硫酸酯两性离子R3P+(CH2)nS2O3â的合成与结构表征，其中R为苯基或丁基，n为3、4、6、8或10，这些化合物作为阳离子型掩蔽硫醇盐配体，用于功能化金纳米粒子，具有作为新型生物诊断识别系统的潜力。这些配体是通过用硫代硫酸钠处理Ï-溴代烷基磷盐来制备的。我们对(R=苯基，n=3)和(R=丁基，n=3)两性离子的晶体和分子结构进行了测定。通过在二氯甲烷-水体系中，在两性离子存在下用硼氢化钠还原四氯金酸钾，制备了一系列分散于水的膦氧烷基硫醇盐包覆的金纳米粒子。紫外-可见光谱和扫描透射电子显微镜表明存在直径约为5纳米的包覆纳米粒子。
• One-Pot Synthesis of Fused Benzo[c]carbazoles by Photochemical Intramolecular Annulation of 3-Acyl-2-haloindoles with Tethered Styrenes
  作者：Shen-Ci Lu、Shi-Chao Wei、Wei-Xia Wang、Wei Zhang、Zhi-Feng Tu

  DOI：10.1002/ejoc.201100876

  日期：2011.10

  the synthesis of fused benzo[c]carbazoles has been achieved in moderate to high yields by the one-pot photochemical annulation of 3-acyl-2-haloindoles with tethered styrenes by photoinduced electron-transfer coupling, electrocyclic reactions, and deacylative aromatization in the presence of pyridine. Fused furo[2,3-c]carbazoles were also synthesized under the same conditions. 5,6-Dihydrobenzo[c]pyrrolo[1

  3-酰基-2-卤代吲哚与系留苯乙烯的一锅光化学环化反应，通过光诱导电子转移偶联、电环反应和高产率合成稠合苯并[c]咔唑的有效方法。在吡啶存在下进行脱酰基芳构化。稠合呋喃[2,3-c]咔唑也在相同条件下合成。5,6-二氢苯并[c]吡咯并[1,2,3-lm]咔唑通过DDQ氧化得到芳香苯并[c]吡咯并[1,2,3-lm]咔唑产物，产率中等至高。
• [EN] DEFEROXAMINE DERIVATIVES AS MEDICAMENTS<br/>[FR] DÉRIVÉS DE DÉFÉROXAMINE UTILISÉS EN TANT QUE MÉDICAMENTS
  申请人：BIOTECHNOLOGICKY USTAV AV CR V V I

  公开号：WO2019015701A1

  公开（公告）日：2019-01-24

  The present invention provides deferoxamine derivatives of general formula I and pharmaceutically acceptable salts thereof, (I) wherein at least one of R1 and R2 is a substituent of formula II. The novel derivatives are particularly suitable as medicaments, preferably for the treatment of cancer. Pharmaceutical preparations of compounds of formula I and a metal, preferably gallium, are also provided, resulting in even more active medicaments or contrast agents. Combinations with other agents, resulting in synergistic effects, are provided.

  本发明提供了通式I的去铁胺衍生物及其药用盐，其中R1和R2中至少有一个是通式II的取代基。这些新颖的衍生物特别适用作药物，优选用于癌症治疗。还提供了通式I化合物和金属，优选为镓的药用制剂，从而产生更活性的药物或对比剂。提供了与其他药剂的组合，产生协同效应。
• 유전자 비독성 항암 치료를 위한 항생제 변형 항암제 화합물 및 이를 포함하는 항암 약학 조성물
  申请人：Korea University Research and Business Foundation 고려대학교 산학협력단(220040170680) BRN ▼209-82-08298

  公开号：KR20210093601A

  公开（公告）日：2021-07-28

  본 발명은 유전자 비독성 항암 치료를 위한 항생제 변형 항암제 화합물 및 이를 포함하는 항암 약학 조성물에 관한 것으로서, 본 발명에 따른 변형 항생제 항암 약물은 암세포의 미토콘드리아만을 표적하는 방식으로 치료 효과를 내기 때문에 핵 DNA를 손상시켜 암세포를 사멸시키는 기존의 화학요법과는 달리 유전자 변성을 일으키지 않아 암의 재발을 예방할 수 있으며, 또한 본 발명에 따른 화합물을 이용한 미토콘드리아 표적 치료법은 일반적인 항암 치료에 의해 약물 저항성을 획득해 치료가 어려운 악성 종양을 효과적으로 치료할 수 있다.

  本发明涉及一种用于基因非毒性抗癌治疗的抗生素改良抗癌化合物以及包含该化合物的抗癌药物组合物，根据本发明，改良抗生素抗癌药物通过定位癌细胞的线粒体来产生治疗效果，与传统的化学疗法通过损害细胞核DNA以消灭癌细胞的方式不同，不会引起基因突变，从而可以预防癌症的复发。此外，利用本发明的化合物进行线粒体定位治疗法可以有效治疗因常规抗癌治疗导致药物耐药性而难以治疗的恶性肿瘤。
• REPURPOSED ANTIBIOTICS FOR NON-NUCLEAR GENOTOXIC CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER CONTAINING THE SAME
  申请人：Korea University Research and Business Foundation

  公开号：US20220000887A1

  公开（公告）日：2022-01-06

  The present invention relates to a repurposed antibiotic compound for the treatment of cancer with minimal nuclear gene damage and an anticancer pharmaceutical composition comprising same. Since the repurposed antibiotic compound has a therapeutic effect in a manner that targets only the mitochondria of cancer cells, the modified antibiotic compound does not cause gene degeneration unlike conventional chemotherapy which damages nuclear DNAs to kill cancer cells, thereby preventing the recurrence of cancer. In addition, a mitochondria targeted therapy using the compound according to the present invention can effectively treat malignant tumors that are difficult to treat due to acquiring drug resistance by general anticancer treatment.

  本发明涉及一种用于治疗癌症的重组抗生素化合物，其对核基因损伤最小，并且包括相同化合物的抗癌药物组合物。由于这种重组抗生素化合物以仅靶向癌细胞的线粒体的方式发挥治疗作用，修改后的抗生素化合物不会像传统化疗那样损害核DNA以杀死癌细胞，从而预防癌症的复发。此外，根据本发明使用该化合物的线粒体靶向疗法可以有效治疗那些由于获得药物耐药性而难以治疗的恶性肿瘤。